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Introduction

26
Non-melanoma skin cancer (NMSC) is the most common cancer among Caucasians. Sporadic basal 27 cell carcinoma (BCC) accounts for 80% of all NMSCs and nodular (nBCC) (40%) and superficial BCC 28 (sBCC) (18-31%), are generally considered to be low-risk tumors. 1 Surgical excision, the gold standard 29 treatment, has cure rates of 95-98%. 8-10 COX-2 is highly expressed in 41 several solid tumors, including BCC. 11 In a phase II clinical trial, systemic NSAIDs reduced both the 42 number and burden of BCCs in patients with basal cell nevus syndrome. 12 Topically applied diclofenac 43 induced a clinical response in the majority of the patients with actinic keratosis, which can be a 44 precursor of squamous cell carcinoma. 13 Calcitriol has anti tumour effects in model systems of 45 several human malignancies derived from prostate, ovary and lungs, which are mainly attributed to 46 stimulation of the vitamin D receptor (VDR).
14 In keratinocytes, the VDR has a regulatory role in SHH 47
and WNT signaling by acting as a tumor suppressor, reducing proliferation and differentiation and 48 inducing apoptosis (fig 1) . 14 
49
We investigated the efficacy of topical application of a NSAID, a vitamin D analogue and the 50 combination on low-risk BCCs, by evaluating the effects on proliferation and apoptosis. Both well-51 3 accepted drugs are already available for other indications. 8 16 or vitamin D (containing) supplements in the preceding 30 days were excluded. The 65 local medical ethics and scientific committee approved the protocol and two following amendments. 66
The study was performed in accordance with the Declaration of Helsinki. All participants provided 67 written informed consent. 68
Enrolled patients with a sBCC or nBCC were randomly assigned to receive either topical diclofenac 69 sodium-3% gel in hyaluronic acid 2·5% (Solaraze®, Almirall, Barcelona, Spain), calcitriol ointment 3 70 µg/g (Silkis®, Galderma, Rotterdam, the Netherlands) (henceforward called diclofenac and calcitriol 71 respectively), a combination of both (combination therapy), or no medication (control group). 72
The primary outcome measure was the post-treatment percentage of cells expressing the 73 immunohistochemical stains Ki-67 and Bcl-2. Ki-67, a proliferation marker, can be detected in the 74 nuclei of proliferating cells. The proto-oncogene Bcl-2, regulating apoptosis, is overexpressed in most 75 BCC.
17 Secondary outcomes were histological tumor regression, adverse events, application-site 76 reactions and patient compliance. 77
78
Assignment and masking 79
Randomization via a computer-generated random allocation scheme was stratified for histological 80 tumor type. Random permuted blocks of eight were used to ensure concealment of allocation. shows that in the control group median values of endpoint Ki-67 expression levels increased slightly 136 when compared with baseline levels. There was a substantial decrease in Ki-67 expression after 137 treatment with diclofenac and combination therapy and a small increase in the calcitriol group. 138
Median values in Bcl-2 expression show a small increase in the control group, whereas there was a 139 slight decrease in tumors treated with diclofenac, calcitriol and combination treatment. 140
The distributions of Ki-67 and Bcl-2 expression levels were skewed and a log(x+1) transformation was 141 used to normalize the distributions. ANCOVA analyses were used to adjust for imbalances in baseline 142 values of Ki-67 and Bcl-2. The mean differences between the treatment groups and the control group 143 were back transformed from the logarithm scale to raw scale and are presented in Table 2 . Ki-67 144 expression was significantly lower in sBCCs treated with diclofenac and combination therapy, when 145 compared to the post treatment levels in the control group(p <0.001 and p=0.012, respectively, table 146 8 2). Also, Bcl-2 expression was significantly lower in sBCCs treated with diclofenac (p=0.001, table 2). 147
Post treatment expression levels in sBCCs treated with calcitriol and in all nBCCs did not differ 148 significantly from those in the control group, neither for Ki-67 nor for Bcl-2 (Table 2) . 149
150
Clinical response and compliance 151
In the sBCC subgroup, histologically complete tumor regression was seen in 64.3% (9 of 14) and in 152 43.8% (7 of 16) of the tumors treated with diclofenac and combination therapy respectively (fig 3) . 153
The difference with the control group (0 of 16) was statistically significant (P=0.0003 and P=0.007, 154 respectively). None of the participants in the calcitriol group showed complete regression. In the 155 nBCC subgroup 31.2% (5 of 16), 6.2% (1 of 16), 33.3% (5 of 15) showed histological complete 156 regression in patients treated with diclofenac, calcitriol or combination therapy, respectively. No 157 residual tumor was observed in 18.8% (3 of 16) of the nBCC control group (fig 3) . Differences 158 between active treatment groups and the control group were not statistically significant. 159
In the sBCC subgroup with no complete tumor regression, a nodular BCC component was found in 160 four tumors assigned to the combination therapy group. In the calcitriol group two tumors with a 161 nodular, and one with an invasive component were found. 162
Median compliance rates were generally high (92.7%-98.2%) and comparable between groups 163 (n=95). 164
165
Adverse events 166
Adverse events were mostly mild to moderate. Erythema, pruritus and erosions at the target tumor 167 site were most frequently reported (table 3). In eight cases the severity of the application-site 168 reactions led to discontinuation of the therapy and prescription of a topical antimicrobial cream. In 169
19.4% (6 of 31) of patients treated with diclofenac and 9.4% (3 of 32) of patients treated with 170 combination therapy, surgical excision was postponed two weeks, due to the severity of application-171 site reactions. Three patients had serious adverse events requiring hospitalization (table 3), but none9 of these serious adverse events were considered to be related to the study medication. No adverse 173 events were reported in the control group. 174 175 176
Discussion
177
This phase II trial provides evidence that topical diclofenac has the potential to clear sBCC, with 178 complete histologic tumor regression in 64.3% (9 of 14) and 43.8% (7 of 16) of the patients treated 179 with diclofenac and combination therapy, respectively. These results are in line with significant 180 decreases of expression levels of the proliferative marker Ki-67 and the anti-apoptotic marker Bcl-2 181 in these treatment groups. Although, application-site reactions were reported frequently, most 182 reactions were of mild to moderate severity, which is in accordance with the literature. 18 Similar 183 reactions are seen in other non-invasive therapies for sBCC, such as imiquimod and 5-fluorouracil 184 cream and probably necessary to achieve tumor regression.
2, 4 Occlusion may have attributed to the 185 severity of the skin reactions. 186
There was no clinical effectiveness of calcitriol. In calcitriol treated sBCCs, slight increases in 187 expression levels of the proliferative marker Ki-67 and slight decreases in the anti-apoptotic marker 188
Bcl-2 were detected, which were not statistically significant. We found no evidence for the 189 Limitations of the study are the small sample size and imbalances in baseline levels of Ki-67 and Bcl-2 220
Despite the small sample size, significant effects of diclofenac treatment in targeting key signaling 221 pathways could be demonstrated and ANCOVA was used to adjust for the differences in baseline 222
levels. 223
This trial provides evidence that topical application of diclofenac 3% gel in 2.5% hyaluronic acid in 224 sBCC significantly reduces proliferation, induces apoptosis and moreover results in significant 225 histological clearance compared to the control group. We therefore conclude that although surgical 226 excision remains the gold standard for all BCC, topical diclofenac may be a promising new treatment 227 for low risk sBCC. Efficacy of topical calcitriol was not observed. Other trials using different 228 concentrations, excipients or combinations of both investigated drugs may be useful to optimize 229 treatment strategies. Also, given the effectiveness of diclofenac gel in treatment of both BCCs and 230 actinic keratosis with only limited side effects, the role for topical diclofenac as a prophylactic agent 231 in NMSC is an interesting subject for future studies. 232
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